The Brain Tumor Center, Duke University Medical Center
Welcome,         Profile    Billing    Logout  
 8 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reardon, David A
NCT03661723: Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Completed
2
60
US
Pembrolizumab, Keytruda, Bevacizumab, Avastin, Re-irradiation
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Glioblastoma
12/21
08/24
SURVIVE, NCT05163080: SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Active, not recruiting
2
247
US
SurVaxM
MimiVax, LLC, Translational Drug Development, Merit
Newly Diagnosed Glioblastoma
08/24
08/24
CA209-324, NCT02648997: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Active, not recruiting
2
40
US
Nivolumab - 240 mg, Opdivo, BMS-936558, ONO-4538, Ipilimumab - 1 mg/kg, BMS-734016, MDX010, MDX-CTLA4, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, External Beam RT
Dana-Farber Cancer Institute, Bristol-Myers Squibb
Meningiomas
12/24
12/25
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
NCT04826393: ASP8374 + Cemiplimab in Recurrent Glioma

Active, not recruiting
1
14
US
ASP8374, cemiplimab, Libtayo
Dana-Farber Cancer Institute, Regeneron Pharmaceuticals, Astellas Pharma Inc
Glioblastoma, Recurrent Glioblastoma
10/22
06/25
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
NCT02287428: Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Recruiting
1
56
US
Radiation Therapy, RT, XRT, Personalized NeoAntigen Peptides, Pembrolizumab, MK-3475, Keytruda, Temozolomide, Concurrent temozolomide; Concurrent TMZ, Adjuvant temozolomide; Adjuvant TMZ, Poly-ICLC, Hiltonol
Dana-Farber Cancer Institute, The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme LLC, National Institutes of Health (NIH)
Glioblastoma
06/25
06/26
NCT05698199: Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)

Active, not recruiting
1
10
US
ITI-1001
Immunomic Therapeutics, Inc.
Glioblastoma
03/26
03/26
Desjardins, Annick
DERIVe, NCT03688178: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab

Active, not recruiting
2
43
US
Human CMV pp65-LAMP mRNA-pulsed autologous DCs, Temozolomide, Temodar, TMZ, Temodal, Varlilumab, anti-CD27, Td, Tetanus-diphtheria (Td) toxoid, Td pre-conditioning, Unpulsed DCs, Unpulsed DCs pre-conditioning
Annick Desjardins, MD, Celldex Therapeutics
Glioblastoma
03/25
03/25
NCT05734560: D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting
1/2
50
US
D2C7-IT, 2141-V11
Darell Bigner, Rockefeller University
Newly Diagnosed MGMT Unmethylated Glioblastoma
02/26
02/28
NCT04547777: Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting
1
30
US
D2C7-IT, 2141-V11, anti-CD40
Darell Bigner, Rockefeller University
Glioma, Malignant
12/24
12/25
NCT06455605: D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Not yet recruiting
1
46
US
D2C7-IT, 2141 V11
Darell Bigner, Rockefeller University
Recurrent Glioblastoma IDH Wildtype
01/29
01/30
NCT05879367: Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Recruiting
1
66
US
Eflornithine (Dose Level 1), DFMO, Eflornithine (Dose Level 2), Eflornithine (Dose Level -1), Temozolomide, Temodar, TMZ
Orbus Therapeutics, Inc.
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
12/24
12/24
DEMAND, NCT04741984: Monocyte Antigen Carrier Cells for Newly Diagnosed GBM

Withdrawn
1
27
NA
MT-201-GBM monocyte vaccine
Michael Gunn, National Cancer Institute (NCI)
Glioblastoma, Glioma, Malignant
05/25
11/25

Download Options